Hi there 👋🏻

This is Clare and Dave from Teleatherapy.

As you may know, Teleatherapy is a platform for providing care to people with Parkinson's disease. We would love for you to join our journey as we:

  1. Expand our direct to consumer offering
  2. Develop and roll out our B2B offering with other clinics
  3. Build partnerships with pharmaceutical & MedTech companies

We would love for you to be a part of our Seed Round and we hope this site helps get you as excited as we are about our future.

Thanks,
Clare & Dave

The Problem

Clare's research and clinical experience led her to identify these problems with care for Parkinson's disease:

For Patients

It's hard for individiuals with Parkinson's disease to access voice therapy. It's expensive and in-person therapy can be physically challenging to attend.

For Speech Therapists

Providing care for Parkinson’s patients is very time-intensive for speech therapists. This limits the number of patients they can have on their caseload and causes a growing waitlist for care.

The Solution

Voice Therapy App

Our patients practice voice therapy each day with a programme tailored to them by their speech therapist.

Exercises are personalised to them, frequency and difficulty of exercises are tuned to their needs — time availablity, cognitive & technological ability and progression of symptoms.

Access care much more easily and much more affordably

Practice as much as they want in their own time

Have their practice monitored by a therapist to improve their care

Care Management Platform

Therapists use our platform to monitor patients' progress and adjust care to their needs.

Our platform learns from therapist decision-making and is able to suggest care interventions based on similar previous cases.

Be more efficient with patients → see more patients

Have better data on patients' progress and deliver better outcomes

Use AI-driven decision-making

Why Parkinson's Disease?

Parkinson's affects 12,000+ people in Ireland and 10,000,000+ worldwide. It's the fastest growing neurodegenerative disease, aided by an aging population and crucially we can have a real impact on the quality of life of individuals with the disease.

Early speech therapy intervention is needed to help slow decline and maintain their voice for up to an additional two years.

Irish Parkinson's Patients
12k+
Global Parkinson's Patients
10m+
Extra Years of Communication
2+

The time is right

Why Now?

As a result of the pandemic, there has been a large movement towards telehealth which would not have been possible a few years ago. In addition, older people have become familiar with video conferencing and mobile devices in order to communicate over the past two years.

Asking an 80-year-old to see a speech & language therapist over zoom would have been a big hurdle just two years ago but is now taken in stride.

And that's not all

Long-term potential growth areas

After achieving product-market fit with our initial offering, we could expand into:

Pharmaceutical Partnerships

The data we collect to monitor patients' voices can correlate voice strength with medication — useful data for the drug manufacturer.

Other Parkinson's Symptoms

With our existing customers we could expand vertically into physical or occupational therapy e.g. helping with tremors or swallowing.

Other Voice Therapy

We could add support for voice therapy for other neurodegenerative diseases (e.g. Motor Neuron Disease) or other speech conditions.

Our Roadmap

Revenue Model

Business Model

We sell licences to our platform as a Software-as-a-Service model. We have focussed on direct-to-consumer so far as it has enabled us to validate and iterate the app. However, our goal is to sell to hospitals & clinics in the US to use with their patients as we can scale much larger that way.

Now

B2C

€75/month

We charge a monthly subscription to patients, often paid for by their Parkinson's association. Currently charging a reduced rate of €75/month during the trial.

This can be reimbursed by the three main health insurance providers in Ireland.

Future

B2B

€100/month

As our focus shifts from B2C to B2B, we will charge clinics €100/month per patient, sold as multi-year contracts with extra capacity.

Rollout strategy

Route-to-Market

B2B Pilot in UK

In order to build out our platform to be used by clinics, we will work with a small number of NHS Parkinson's clinics in the UK. These will be paying customers using an early version of our platform. The goal here is to learn and iterate quickly so that our platform is ready for a full launch after our Series A.

We initially begin with the NHS in the UK as they are in the same timezone, English-speaking and have many more specialty Parkinson's clinics than Ireland. We have two NHS clinics on our waiting list at the moment and expect them to be our first B2B customers. We also plan to trial in the US to test the market before our actual launch.

Inbox user interface

B2B Launch in US

After firming up our platform for a launch and raising a Series A round, our focus will be on expansion into clinics in the US.

We have chosen the US because:

  1. It is the largest healthcare market in the world
  2. We will need to be registered as a medical device and FDA registration is quicker (by years) than CE Mark registration in the EU
  3. English is the predominant language so language is not a barrier

As average deal size will be quite high, we are planning on taking a direct outreach approach. We have our first call with the largest healthcare provider in New York (they have more staff than the HSE) and have validated our approach with a similar startup in the Physiotherapy space.

Customer profile user interface

The Team

Founding Team →

  • Clare Meskill

    Founder & CEO | Qualified & CORU Registered Speech & Language Therapist | Director at the Irish Association of Speech & Language Therapists

    Clare has great clinical & volunteer voice therapy experience working with individuals with Parkinson's. She is currently wrapping up a Masters by research in “The barriers and facilitators for the use of technology amongst individuals with Parkinson's disease, and the codesign process of technology for therapy”. Clare has successfully developed and bootstrapped the business to date.

  • Dave Calnan

    Co-Founder & CTO | Senior Software Engineer

    Dave was the third technical hire at Workvivo, a fast-growing HR Tech business. Dave is a recovering entrepreneur and ready to get back into it - previous endeavours include renovating a cinema into a music venue at 16, building a charitable GroupOn competitor and running a small web design agency. Dave has received the UCC Quercus Innovation & Entrepreneurship Scholarship and represented Ireland in the Global Student Entreprenuer Awards after winning the Irish national competition.

Why us?

With the combination of Clare's academic research & clinical knowledge and Dave's technical experience building a scaling product at speed, we have a strong combined skillset for this MedTech startup.

Together we are able to quickly iterate on a product that works well for patients who may have reduced cognitive abilities or limited tech abilities along with busy therapists in clinics.

The Team (cont)

Employees →

  • Kevin Bourke

    Sales & Marketing Executive

    Kevin joined the team in July 2021 to help grow the B2C pilot. He studied Marketing & Entrepreneurship in college and his focus is growing the sales pipeline.

The Ask

We are raising €500k at a post-raise valuation of €2.5m. We are currently in talks with Enterprise Ireland about matched funding. Our plan is to raise:

  • €250k from Angel Investors
  • €250k from Enterprise Ireland

Will you join us?

We would be thrilled if you would consider an equity investment in Teleatherapy.

We're currently preparing the legal documents to have a term sheet ready to sign.

And that's it - thank you for your time.Please get in touch, we'd love to hear from you.

Call Clare
Email Clare

Teleatherapy

P.S. You might be wondering why we put so much time into this site.

User experience is at the core of what we do. We pay attention to the details to deliver the best experience possible — whether that's for our patients, customers, employees, or investors. We wanted to show you that we'll put this much care into helping our patients & clinics and driving the business forward.

Thanks again,
Clare & Dave

Appendix